Treatment options for managing atherogenic dyslipidemia and fatty liver disease

Risultato della ricerca: Book/Film/Article reviewpeer review

3 Citazioni (Scopus)


Non-alcoholic fatty liver disease (NAFLD) is the most common cause ofchronic liver disease in Western countries with up to 30% of the populationaffected. Since NAFLD is associated with an increased risk of cardiovascular(CV) disease, these patients should be stratified for CV risk factors, includingatherogenic dyslipidemia, and managed accordingly. Lifestyle modificationsrepresent an effective treatment for NAFLD, since most patients areoverweight or obese. Also, promising, but not conclusive, results are availablefor current pharmacologic treatment. Drugs potentially effective againstNAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturatedfatty acids, while there is reluctance to use statins in patients withsuspected or established chronic liver disease. Several other therapeutic optionsare potentially available, and more data are expected from new peroxisomeproliferator-activated receptor agonists and incretin-based therapie
Lingua originaleEnglish
pagine (da-a)1065-1068
Numero di pagine4
RivistaExpert Opinion on Pharmacotherapy
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.3000.3004???
  • ???subjectarea.asjc.2700.2736???


Entra nei temi di ricerca di 'Treatment options for managing atherogenic dyslipidemia and fatty liver disease'. Insieme formano una fingerprint unica.

Cita questo